Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2026-01-25 @ 2:32 AM
Study NCT ID:
NCT05785767
Status:
RECRUITING
Last Update Posted:
2025-11-21
First Post:
2023-03-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
Regeneron Pharmaceuticals
Organization: